An interventional study of Saw palmetto and sanmiaoshan capsule in Prostatic Hyperplasia and Adrenergic Alpha-Antagonists, sponsored by Hospital Authority, Hong Kong. Status unknown at 1 site in China. Open to male participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2010-07-07.
Sponsored by Hospital Authority, Hong Kong · Not applicable, Interventional, and Treatment
The purpose of this study is to assess the effect of saw palmetto and sanmiaoshan, on top of alpha blocker, on urinary flow rate and BPH symptoms in patients with BPH.
783 studies on the registry are indexed under Prostatic Hyperplasia; 174 are open to participants now.
This study's planned enrollment of 40 is below the median of 97 across 593 interventional studies indexed under Prostatic Hyperplasia.
Browse Prostatic Hyperplasia studies →Hospital Authority, Hong Kong is the lead sponsor of 73 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Clinically diagnosed to have BPH:
Exclusion Criteria:
Differences in IPSS between the study medication and placebo groups
Time frame: At study enrolment, after six month of study medication or placebo administration, at the end of washout period and after six month of alternative drug treatment
Differences in Qmax between the study medication and placebo groups
Time frame: At study enrolment, after six month of study medication or placebo administration, at the end of washout period and after six month of alternative drug treatment
Differences in IPSS and Qmax at baseline and at the end of treatment drug / placebo treatment
Time frame: From study enrolment/ after washout period to the end of study medication / placebo administration
Mean urinary flow rate, post-void residual volume, prostate volume, PSA and GHQ score between study medication group and placebo group
Time frame: At study enrolment, after six month of study medication or placebo administration, at the end of washout period and after six month of alternative drug treatment
Mean urinary flow rate, post-void residual volume, prostate volume, PSA and GHQ score between study medication group and baseline, and placebo group and baseline
Time frame: From study enrolment/ after washout period to the end of study medication / placebo administration
This study is status unknown, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Authority, Hong Kong